Clinical Trial Update: Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing Capecitabine plus Bevacizumab versus Capecitabine plus Irinotecan plus Bevacizumab as first-line therapy in metastatic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Colorectal Cancer Metastatic | Phase 3 | Status: UNKNOWN